ProPhase Labs is currently seeking ways to meet ... The esophageal cancer test could be commercialized by late 2025 or early 2026, targeting a market worth $7 to $14 billion.

ProPhase Labs announced plans to launch DNA ... The company's esophageal cancer test, expected to be commercialized by late 2025 or early 2026, targets a market worth $7 to $14 billion.

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered ...

ProPhase Labs, Inc. GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer ...

The process of cell division, or mitosis, has fascinated biologists since its discovery in the late 1870s ... first become visible within the prophase nucleus. The subsequent breakdown of the ...

ProPhase Labs, Inc. announced that CEO Ted Karkus will present at the upcoming Investor Summit Virtual on March 11, 2025, at 1:30 P.M. ET, offering investors insights into the company's operations ...